Verzenio (Abemaciclib) Patent Expiration, LOE Window & CMS Spending

Verzenio (Abemaciclib) by Eli Lilly: FDA Orange Book core substance LOE 2031-09-28, 0 AB generics, $1.45B 2024 CMS Part D & Medicaid spend, and 16 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN208716 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-09-28
Last Listed Patent or Exclusivity Date2031-09-28
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.45B
2024 Medicare Part D Spend$1.06B
2024 Medicaid Spend$393.9M
Reported Wholesale Price Change (CA SB 17)16 WAC filings (max 19.1% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.